| References: |
BI-97C1 potently inhibits cell growth of human prostate cancer, lung cancer, and lymphoma cell lines with EC50 values of 0.13, 0.56, and 0.049 μM, respectively, and shows little cytotoxicity against bax-/-bak-/- cells. It is suggest that treatment with the combination regimen of mda-7/IL-24 and BI-97C1 induces autophagy that facilitates apoptosis in association with up-regulation of NOXA, accumulation of Bim, and activation of Bax and Bak.BI-97C1 displays in vivo efficacy in transgenic mice in which Bcl-2 is overexpressed in splenic B-cells and also demonstrates superior single-agent antitumor efficacy in a prostate cancer mouse xenograft model that depends on Mcl-1 for survival. Treatment with Ad.5/3-mda-7 and BI-97C1 significantly inhibits the growth of human PC xenografts in nude mice and spontaneously induced PC in Hi-myc transgenic mice. Tumor growth inhibition correlats with increased TUNEL staining and decreased Ki-67 expression in both PC xenografts and prostates of Hi-myc mice. For the detailed information of Sabutoclax, the solubility of Sabutoclax in water, the solubility of Sabutoclax in DMSO, the solubility of Sabutoclax in PBS buffer, the animal experiment (test) of Sabutoclax, the cell expriment (test) of Sabutoclax, the in vivo, in vitro and clinical trial test of Sabutoclax, the EC50, IC50,and affinity,of Sabutoclax, For the detailed information of Sabutoclax, the solubility of Sabutoclax in water, the solubility of Sabutoclax in DMSO, the solubility of Sabutoclax in PBS buffer, the animal experiment (test) of Sabutoclax, the cell expriment (test) of Sabutoclax, the in vivo, in vitro and clinical trial test of Sabutoclax, the EC50, IC50,and affinity,of Sabutoclax, Please contact DC Chemicals. |
